Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.

Leukemia - 1 Jul 2017

Jones D, Woyach J A, Zhao W, Caruthers S, Tu H, Coleman J, Byrd J C, Johnson A J, Lozanski G

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Agammaglobulinaemia Tyrosine Kinase
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phospholipase C gamma

Share to Piperidines

Share to Protein-Tyrosine Kinases

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 28366935
DOI: 10.1038/leu.2017.110

Genes

PLCG2
BTK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.PMID 28366935Read ↗

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Semantic proximity Read ↗

PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia.Semantic proximity Read ↗

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell MalignanciesSemantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.Semantic proximity Read ↗

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSemantic proximity Read ↗

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.Semantic proximity Read ↗

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitorsSemantic proximity Read ↗

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.Semantic proximity Read ↗

Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel AgentsSemantic proximity Read ↗

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.